Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0032285 (pneumonia)
 54,520 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Ampicillin introduced in 1961 has been administered in the treatment of diverse infections by both oral and parenteral means. Oral infections of the upper airways such as otitis media, bronchitis, and pneumonia have responded with high success rates since the microorganisms involved have remained sensitive to ampicillin. Similarly, out-patient urinary tract infections caused by Escherichia coli, Proteus mirabilis, and enterococci are cured. Typhoid fever may yet be treated with ampicillin, but shigellosis has become refractory with the development of resistant strains. Ampicillin has assumed a prominent role in the treatment of gonorrhoea. Parenteral ampicillin is still a mainstay of the treatment of Hemophilus meningitis, but the recent appearance of ampicillin resistant strains may become a serious problem. A number of derivatives and analogues of ampicillin have been developed. Among the compounds, hetacillin, metampicillin and pivampicillin which hydrolyze in the body to yield ampicillin, only pivampicillin appears to offer advantage over the parent compound. Blood levels are twice those of a comparable dose of ampicillin. However, more comparisons with ampicillin in clinical situations are needed. The other analogues of ampicillin are epicillin, cyclacillin and amoxicillin. Epicillin has no superiority to ampicillin, and the cyclacillin data do not show clear superiority over ampicillin in spite of initially high blood levels, since the compound is less active and so rapidly cleared from the body. Amoxicillin, on the other hand, has been shown to have it vitro activity equal to ampicillin and to produce higher blood levels for a longer period of time. Clinical studies have substantiated efficacy in treatment of otitis media, pharyngitis, bronchitis, pneumonitis, and urinary tract infections at doses half those of ampicillin. It has been effective in gonorrhoea and typhoid, but not in shigellosis. It would seem that to date only pivampicillin and amoxicillin, particularly the later, should be considered as replacements of ampicillin in oral therapy.
 ...
PMID:Aminopenicillins - clinical pharmacology and use in disease states. 109 2

In the winter of 1972-1973 a multicentre trial of the treatment of upper and lower respiratory tract infections was carried out in Spain using doxycycline. 85 physicians participated in the study and treated 1,653 patients. The infections included acute bronchitis, acute exacerbation of chronic bronchitis, pneumonia, bronchopneumonia, tonsillitis, pharyngitis, trachetis, sinusitis, and otitis media. The majority of the patients were adult out-patients although some children and adolescents were included: 1,011 of the patients were male and 642 female. A number of the signs of respiratory infection such as temperature, cough, pain and inflammatory symptoms were examined. A rapid reduction in intensity and severity was noted in all of these parameters. Tolerance to the antibiotic was excellent. Only minor side-effects were reported and these were mild and mainly limited to the gastro-intestinal tract - in no case was treatment discontinued. The total number of side-effects was 37; they occurred in 31 out of the 1,653 patients. The overall evaluation of results showed a very good or good response in 85% of the patients. It appears from this multicentre study that the efficacy of doxycycline has in no way decreased over the 7 years of its extensive use in Spain. It remains a fast acting and effective antibiotic in upper and lower respiratory tract infections irrespective of age, sex or diagnosis.
 ...
PMID:Doxycycline in respiratory tract infections. Report of a retrospective study in Spain during the winter 1972-1973. 109 76

Inactivated Mycoplasma pneumoniae vaccine produced antibody responses that reached protective levels in most individuals. These were almost equivalent to natural infection in amount and duration, and they persisted more than a year. Adverse effects were inconsequential. At Keesler Air Force Base, Mississippi, where the annual rate of mycoplasma pneumonia varied from 20 to 50 per 1000 since 1959, protection studies were conducted in 21, 199 men in 1964-1966 and in 13, 892 men in 1969-1971. This produced a 36 percent reduction in bronchitis and a 45 percent reduction in pneumonia due to all etiologies in the frist study and 37 percent and 48 percent respectively in the second study. The protective efficacy of the second vaccine was 87 percent for acutebronchitis and 66 percent for pneumonia due to Mycoplasma pneumoniae. Persons who developed Mycoplasma pneumoniae infections in spite of vaccination did not experience more severe illnesses.
 ...
PMID:Efficacy of inactivated Mycoplasma pneumoniae vaccine in man. 112 87

The entry of ampicillin, cephalothin and gentamicin into traceobronchopulmonary secretions/exudates was assessed in 22 patients during 28, episodes of pneumonia or bronchitis. Specimens were collected from the lower respiratory tract via tracheostomies or endotracheal tubes using either the flexible fiberoptic bronchoscope (50 specimens) or an intratracheal catheter (59 specimens). Venous blood was obtained at the same time. The concentrations in the bronchial specimens were less than those in the corresponding serums, amounting to about 10 per cent with ampicillin, 25 per cent with cephalothin and equal to or greater than 40 per cent with gentamicin.
 ...
PMID:Penetration of antimicrobial agents into bronchial secretions. 115 79

Immunelektrophoreses and quantitative determinations of serum immunglobulins were performed for 298 children with infections of the upper and lower respiratory tract, chronic and recurrent infections, pyelonephritis and Salmonella infections. Minor changes were seen for IgG, 80% of the patients had levels within the normal range. Many patients, however had increased levels of IgA and IgM, while a decrease of these immunglobulins below the normal range were rarely detected. Children with upper respiratory tract infections had increased IgA in 28 per cent and increased IgM in 44 per cent, those with bronchitis in 21 per cent an IgA and in 45 an IgM increase. Most frequently immunglobulin elevations were seen in patients with pneumonia: IgA was in 50% and IgM in 67% increased above the normal range. Patients with recurrent infections had an IgA elevation in 34% and an IgM increase in 33%. 35% of children with pyelonephritis had an IgA and IgM increase. Children suffering from Salmonella infections had an increased IgA in 29 and IgM in 67%. The result of other authors and of factors leading to an elevation of serum immunglobulins are discussed.
 ...
PMID:[Quantitative changes of serum immunglobulins during infectous diseases in childhood (author's transl)]. 117 57

The frequency of asthma in 10 971 school-children between the ages of 5 and 14 years was reported by their parents to be 3-8%. Of these, 20-7% were said to have had bronchitis, 5-9% pneumonia, and 4-7% eczema. Asthma was reported more commonly in boys than girls and was greatest in children of social classes I and II. One-third of the children were reported to have their first attack before the age of 2 years. Few (18%) first attacks started after the age of 5 years. There was no evidence that bronchitis predisposed to the later development of asthma, or vice versa. Within each age-sex group children with a history of asthma had lower peak expiratory flow rates than children who gave no such history. These diffences in PEFR were greater than for children with a history of bronchitis.
 ...
PMID:Asthma in schoolchildren. Demographic associations and peak expiratory flow rates compared in children with bronchitis. 122 Aug 34

Bronchial suction-drainage in infants--according to our observations--is a life-saving procedure in cases of aspiration, severe bronchitis and retention of bronchial secretion. It can also be very effective in atelectasis, bronchopneumonia and pulmonary abscess. The earlier the drainage the quicker the clearing up of the atelectasis. An additional indication for performing bronchial suction in severe lower respiratory tract infections is to gagain secretion for bacterial culture. This is especially important in the Gram negative and Staphylococcus infections of young infants. The right upper pulmonary lobe is the most common localisation for atelectasis and pneumonia in this age group. One possible explanation for this could be that malformed bronchi are more frequently found in the right than in the left upper lobe. It is such a characteristical phenomenon in infancy that we called it "the right upper lobe syndrome".
 ...
PMID:[The therapeutic significance of bronchial suction-drainage in infants]. 125 54

Amoxicillin at a daily dose of 1-1.5 g was orally administered to total 30 cases comprising 6 of acute tonsillitis, 6 of chronic tonsillitis, 8 of acute bronchitis, 4 of chronic bronchitis, 4 of bronchiectasis, 1 of suppurative diseases of the lung and 1 of exudative pleurisy. The clinical results and side effects are reported. 1. The effect of amoxicillin was remarkably good in 15 of 30 cases with infections of respiratory apparatus (50%), good in 7(23%), poor in 5(17%) and unknown in 3(10%); the effectiveness was 73%. 2. In terms of diseases, amoxicillin was effective in 33% of acute tonsillitis, in 50% of chronic tonsillitis and in all of acute bronchitis, chronic bronchitis, bronchiectasia and suppurative disease of the lung. No effect was observed in exudative pleurisy. 3. In terms of strains detected, amoxicillin was effective in 67% of Staphylococcus aureus, in 89% of Haemophilus and in 50% of Klebsiella. This drug was effective in all cases caused by Escherichia coli, Acinetobacter calcoacetines, beta-Streptococcus, Flavobacterium, Streptococcus pneumonia, though these strains were not frequently detected. Pseudomonas aeruginosa had no response to this drug. 4. Two cases of transient hepatic dysfunction, 6 of eruption, 5 of gastro-intestinal disorders, 1 of arthralgia and 1 of pyrexia were observed as side effects (some cases had side effects in overlap).
 ...
PMID:[Clinical trials with amoxicillin (Pasetocin 'Kyowa') on infections of respiratory apparatus (author's transl)]. 127 87

Cefprozil (CFPZ, BMY-28100), a new oral cephalosporin, was evaluated for its antibacterial activity and clinical efficacy. Thirty-four patients were treated with 7.7-36.2 mg/kg per day of CFPZ divided into 3 times. A total of 33 patients including 3 with acute pneumonia, 2 with acute bronchitis, 17 with acute upper respiratory tract infections, 4 with urinary tract infections, 1 with suppurative lymphadenitis and 6 with other soft tissue infections were evaluated for clinical efficacy except for 1 patient whose general conditions were too serious to continue to be treated with orally medication. Clinical effects were excellent in 8 patients and good in 23 but 2 cases were excluded because they were suspected for viral infections, hence the overall efficacy rate was 100%. Bacteriological responses were confirmed on 6 (66.7%) strains which were eradicated by the treatment out of 9 strains identified. CFPZ showed stronger antibacterial activities than those of cefaclor. Side effects or abnormal laboratory test results were observed in 2 patients; nausea and pallor of face in 1 patient and an increase of eosinophil in 1. The above findings suggest that CFPZ is a safe and useful antibiotics for the treatment of bacterial infections in pediatric patients.
 ...
PMID:[Clinical evaluation of a new oral cephalosporin, cefprozil, in pediatrics]. 128 81

Cefprozil (CFPZ), a newly developed oral cephalosporin in a fine granular form for pediatric use, was administered to children with bacterial infections. MICs were determined for 6 drugs including CFPZ, cephalexin (CEX), cefaclor (CCL), ampicillin (ABPC), methicillin (DMPPC) and cloxacillin (MCIPC) against the following 84 strains isolated from cases to which CFPZ was administered; 55 strains of Gram-positive cocci (GPC) including 2 strains of Staphylococcus aureus, 49 strains of Streptococcus pyogenes, 4 strains of Streptococcus pneumoniae, and 29 strains of Gram-negative bacilli (GNB) including 10 strains of Haemophilus influenzae, 18 strains of Escherichia coli, and 1 strain of Proteus mirabilis. MIC determination of these strains was done with an inoculum size of 10(6) CFU/ml. In pharmacokinetic studies, serum concentrations, urinary concentrations and urinary recovery rates were investigated using bioassay and high-performance liquid chromatography (HPLC). CFPZ was orally administered 30 minutes before meals to 9 children with ages ranging from 7 years and 1 month to 12 years and 3 months. Three groups of 3 children were tested with doses of 4.0, 7.5 and 15.0 mg/kg, respectively. In addition to the above, clinical and bacteriological studies were performed in a total of 160 cases consisting of children with ages ranging 5 months to 12 years and 5 months. A mean dose of 8.6 mg/kg in 3-4 divided doses (130 cases of t.i.d. and 30 cases of q.i.d.) was administered for an average of 7 days. The 160 cases included 34 cases of pharyngitis, 5 cases of tonsillitis, 8 cases of acute bronchitis, 8 cases of pneumonia, 52 cases of scarlet fever, 4 cases of acute purulent otitis media, 47 cases of urinary tract infection, 1 case of purulent lymphadenitis and 1 case of posthitis. Adverse reactions and abnormal clinical laboratory test results were also examined in 166 cases, including 6 cases excluded from the evaluation of clinical efficacy. The results obtained are summarized as follows: 1. With regard to GPC, MICs of CFPZ against 2 strains of S. aureus were 0.78 or 1.56 micrograms/ml and CFPZ showed the second highest activity to MCIPC. MICs of CFPZ against 49 strains of S. pyogenes were all less than 0.025 micrograms/ml.(ABSTRACT TRUNCATED AT 400 WORDS)
 ...
PMID:[Pharmacokinetic and clinical studies on cefprozil granules in the pediatric field]. 128 89


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>